Hepatic Uptake of Tc-99m DPD on Bone Scintigraphy

PURPOSE: There are various etiologies, which can result in nonosseous, nonurologic uptake in bone scintigraphy. This study aimed to evaluate the influence of the interval between gadolinium (Gd)-containing contrast of MRI and Tc-99m DPD (Tc-99m 3,3-diphosphono-1,2-propanedicarboxylic acid) on bone scintigraphy. MATERIALS AND METHODS: We retrospectively analyzed 1028 patients with bone scintigraphy performed between January 2010 and February 2011. All these 1028 patients had MRI contrast administration prior to bone scintigraphy. Fifty patients (8 women, 42 men) showed hepatic uptake on bone scintigraphy. The patients were subdivided into 2 groups (group A: MRI performed on the same day with bone scintigraphy, group B: MRI performed 1 or 2 days before bone scintigraphy). RESULTS: Among 1028 subjects, hepatic uptake in patients with MRI and bone scintigraphy on the same day was shown in 39 of the 585 bone scintigraphies (6.67%), while hepatic uptake with interval of 1 and 2 days was visualized in 8 of the 186 (4.30%) and 3 of the 87 (3.45%) subjects. No patients with interval more than 2 days showed hepatic uptake of bone scintigraphy. CONCLUSION: The interval between MRI with Gd-contrast and bone scintigraphy has an influence on hepatic uptake. Gd-containing contrast injection before bone scintigraphy within 2 days might affect the nonosseous uptake of Tc-99m DPD. At least 2 days of interval between MRI and bone scintigraphy might be needed to avoid hepatic uptake of bone scintigraphy.